Overview

A Study of Golimumab in the Treatment of Indian Participants With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis

Status:
Active, not recruiting

Trial end date:
2022-01-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the safety of subcutaneous (SC) golimumab in participants with active Ankylosing Spondylitis (AS) or Psoriatic Arthritis (PsA) over 24 weeks.

Phase:

Phase 4

Details

Lead Sponsor:

Johnson & Johnson Private Limited

Treatments:

Antibodies, Monoclonal
Golimumab